Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ERYTHROCIN STEARATE.
E.E.S. vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic